title: Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention.
abstract: The cardiovascular profile of the apelin makes it a promising therapeutic target for heart failure and ischemic heart disease. However, it remains unknown whether apelin affect the clinical outcome of patients with ST elevation myocardial infarction (STEMI) and received percutaneous coronary intervention (PCI). We enrolled a total of 120 patients with acute STEMI who underwent primary PCI. Serum apelin was detected. After PCI procedure, all patients were followed for 12 months. The follow-up end-point was occurrence of major adverse cardiovascular event (MACE). Lower serum apelin levels (<0.54 ng/mL) was significantly associated with higher serum low density lipoprotein-cholesterol level, higher peak creatine kinase MB fraction (CK-MB) and peak troponin-I (TNI) levels, the number of obstructed vessels, and need for inotropic support. The incidence of MACE was significantly higher in the low apelin group (23 patients out of 67) than in the high apelin group (10 patients out of 75, P < 0.001). Kaplan-Meier analysis revealed that the MACE-free rate was significantly lower in the patients with low apelin than those with high apelin (P < 0.001, log rank test). The multivariate Cox proportional hazard analysis adjusted with the clinical and angiographic characteristic reveals that the serum low apelin is a predictor for MACE incidence (hazard ratio = 2.36, 95% confidence interval: 1.83-3.87, P = 0.004). The finding of this study suggests that the serum apelin may be used as a marker to predict the MACE after PCI in patients with STEMI.
authors: From the Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
authors: Hai-Tao
authors: HT
authors: Liu
authors: Mai
authors: M
authors: Chen
authors: Jin
authors: J
authors: Yu
authors: Wei-Jie
authors: WJ
authors: Li
authors: Ling
authors: L
authors: Tao
authors: Yan
authors: Y
authors: Li
authors: Wen-Yi
authors: WY
authors: Guo
authors: Hai-Chang
authors: HC
authors: Wang
mesh_terms: D000073861:Apelin; D015415:Biomarkers / Q000097:blood; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002681:China / Q000453:epidemiology; D008078:Cholesterol, LDL / Q000097:blood; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000000981:diagnostic imaging; D052279:Creatine Kinase, MB Form / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology / Q000628:therapy; D062645:Percutaneous Coronary Intervention; D012008:Recurrence; D020521:Stroke / Q000097:blood / Q000453:epidemiology; D019210:Troponin I / Q000097:blood
chemical_list: C115436:APLN protein, human; D000073861:Apelin; D015415:Biomarkers; D002316:Cardiotonic Agents; D008078:Cholesterol, LDL; D036341:Intercellular Signaling Peptides and Proteins; D019210:Troponin I; D052279:Creatine Kinase, MB Form
references: Eur J Pharmacol. 2006 Dec 28;553(1-3):222-8
references: 17055480
references: Biochem Pharmacol. 2008 May 15;75(10):1882-92
references: 18272138
references: Eur J Heart Fail. 2006 Jun;8(4):355-60
references: 16464638
references: PLoS One. 2013 Sep 06;8(9):e71041
references: 24039710
references: Heart Vessels. 2010 Sep;25(5):363-7
references: 20676956
references: Hypertension. 2009 Sep;54(3):598-604
references: 19597036
references: Circulation. 2004 Sep 14;110(11 Suppl 1):II187-93
references: 15364861
references: Peptides. 2009 Jun;30(6):1144-52
references: 19463748
references: Mol Cell Biochem. 2010 Feb;335(1-2):13-7
references: 19728040
references: J Mol Med (Berl). 2014 May;92(5):487-95
references: 24370940
references: Clin Chim Acta. 2010 Dec 14;411(23-24):2014-8
references: 20736001
references: Regul Pept. 2006 Jan 15;133(1-3):147-54
references: 16278022
references: Cardiovasc Drugs Ther. 2006 Apr;20(2):85-91
references: 16761189
references: Heart Vessels. 2014 Sep;29(5):679-89
references: 24141989
references: Neuromolecular Med. 2014 Sep;16(3):578-86
references: 24929654
references: Eur J Heart Fail. 2008 Aug;10(8):725-32
references: 18583184
references: Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1329-35
references: 19304942
references: PLoS One. 2014 Oct 09;9(10):e109523
references: 25299576
references: Adv Med Sci. 2011;56(2):222-30
references: 21940265
references: Cardiovasc Diabetol. 2014 Apr 14;13:78
references: 24725502
references: Scand J Clin Lab Invest. 2010 Oct;70(6):421-7
references: 20645679
references: Clin Chim Acta. 2008 Feb;388(1-2):200-3
references: 18054331
references: J Cell Mol Med. 2015 Jan;19(1):53-61
references: 25311234
references: Circulation. 2010 Apr 27;121(16):1818-27
references: 20385929
references: Clin Chim Acta. 2008 Sep;395(1-2):130-3
references: 18582450
references: J Cardiovasc Med (Hagerstown). 2012 Dec;13(12):819-27
references: 22772599